Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186 Harris AL (1997) Antiangiogenesis for cancer therapy. Lancet 349:13–15 Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19:7–16 Kerbel RS (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13:31–36 Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505–515 Scappaticci FA (2002) Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20:3906–3927 Hudis CA (2005) Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 19:26–31 Teicher BA (1999) Combination of antiangiogenic agents with standard cytotoxic therapies in therapeutic regimens. Clin Cancer Res 5:3878s–3879s Denekamp J (1993) Review article: angiogenesis, neovascular proliferation and vascular pathophysiolgy as targets for cancer therapy. Br J Radiol 66:181–196 Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045–1047 Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15–R24 Browder T, Butterfield CE, Kraling BM et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886 Belotti D, Vergani V, Drudis T et al (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843–1849 Hotchkiss KA, Ashton AW, Sparano J et al (2000) Inhibition of endothelial cell function by docetaxel (Taxotere). Proc Am Assoc Cancer Res 41:647 Hainsworth JD, Burris HA III, Greco FA (1999) Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Oncol 26:19–24 Sweeney CJ, Miller KD, Sissons SE et al (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369–3372 Sweeney CJ, Sissions SE, Nozaki S et al (2000) Overcoming resistance to the anti-angiogenic properties of docetaxel induced by endothelial cell stimulation. Proc Am Assoc Cancer Res 41:647 D’Amato RJ, Loughnan MS, Flynn E et al (1994) Thalidomide in an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082–4085 Sampaio EP, Sarno EN, Galilly R et al (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:699–703 Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216 Shimizu K, Oku N (2004) Cancer anti-angiogenic therapy. Biol Pharm Bull 27:599–605 Kerbel RS (1997) A cancer therapy resistant to resistance. Nature 390:335–336 Abraham D, Abri S, Hofmann M et al (2003) Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. J Urol 170:1388–1393 Bello L, Carrabba G, Giussani C et al (2001) Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61:7501–7506 Klement G, Huang P, Mayer B et al (2002) Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8:221–232 Man S, Bocci G, Francia G et al (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731–2735 Mauceri HJ, Seetharam S, Beckett MA et al (2002) Angiostatin potentiates cyclophosphamide treatment of metastatic disease. Cancer Chemother Pharmacol 50:412–418 Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23:939–952 Takahashi N, Haba A, Matsuno F et al (2001) Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 61:7846–7854 Teicher BA, Holden SA, Ara G et al (1994) Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 57:920–925 Teicher BA, Sotomayor EA, Huang ZD (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702–6704 Vogt T, Hafner C, Bross K et al (2003) Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98:2251–2256 Spieth K, Kaufmann R, Gille J (2003) Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 52:377–382 Gille J, Spieth K, Kaufmann R (2005) Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. J Dtsch Dermatol Ges 3:26–32 Hafner C, Reichle A, Vogt T (2005) New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARg agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr Cancer Drug Targets 5:393–419 McDermott DF, Cho DC, Merchan JR et al (2006) A phase II pilot trial of low dose, continuous infusion, or “metronomic”, paclitaxel and oral celecoxib in patients with metastatic melanoma. Proc Am Assoc Cancer Res 24:8010 Orlando L, Cardillo A, Ghisini R et al (2006) Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 6:225 Sterba J, Valik D, Mudry P et al (2006) Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie 29:308–313 Young SD, Whissell M, Noble JC et al (2006) Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 12:3092–3098 Colleoni M, Orlando L, Sanna G et al (2006) Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17:232–238 Kesari S, Schiff D, Doherty L et al (2006) Phase II study of antiangiogenic (metronomic) chemotherapy for recurrent malignant gliomas. Proc Am Assoc Cancer Res 24:1569 Kieran MW, Turner CD, Rubin JB et al (2005) A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27:573–581 Suvannasankha A, Fausel C, Juliar BE et al (2007) Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21. Oncologist 12:99–106 Dahut WL, Gulley JL, Arlen PM et al (2004) Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22:2532–2539 Figg WD, Retter A, Steinberg SM et al (2005) Inhibition of angiogenesis: thalidomide or low-molecular weight heparin? J Clin Oncol 23:2113–2114 Horne MK III, Figg WD, Arlen P et al (2003) Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 23:315–318 Behrens RJ, Gulley JL, Dahut WL (2003) Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther 10:228–232 Zangari M, Anaissie E, Barlogie B et al (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614–1615 Horstmann E, McCabe MS, Grochow L et al (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895–904